Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,516 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.
Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA, Fenske TS, Barr PM, Phillips T, Leblanc M, Fisher RI, Cheson BD, Smith SM, Faham M, Wilkins J, Leonard JP, Kahl BS, Friedberg JW. Chen RW, et al. Among authors: smith sm. Br J Haematol. 2017 Mar;176(5):759-769. doi: 10.1111/bjh.14480. Epub 2016 Dec 19. Br J Haematol. 2017. PMID: 27992063 Free PMC article. Clinical Trial.
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.
Poiré X, Kline J, Grinblatt D, Zimmerman T, Conner K, Muhs C, Gajewski T, Van Besien K, Smith SM. Poiré X, et al. Among authors: smith sm. Leuk Lymphoma. 2010 Jul;51(7):1241-50. doi: 10.3109/10428194.2010.486876. Leuk Lymphoma. 2010. PMID: 20496994 Clinical Trial.
T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse.
Kenkre VP, Horowitz S, Artz AS, Liao C, Cohen KS, Godley LA, Kline JP, Smith SM, Stock W, van Besien K. Kenkre VP, et al. Among authors: smith sm. Leuk Lymphoma. 2011 Feb;52(2):214-22. doi: 10.3109/10428194.2010.538777. Epub 2010 Dec 10. Leuk Lymphoma. 2011. PMID: 21142785 Free PMC article.
Analysis of very elderly (≥80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome.
Nabhan C, Smith SM, Helenowski I, Ramsdale E, Parsons B, Karmali R, Feliciano J, Hanson B, Smith S, McKoy J, Larsen A, Hantel A, Gregory S, Evens AM. Nabhan C, et al. Among authors: smith sm, smith s. Br J Haematol. 2012 Jan;156(2):196-204. doi: 10.1111/j.1365-2141.2011.08934.x. Epub 2011 Nov 16. Br J Haematol. 2012. PMID: 22084970 Free article.
Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?
Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR, Bredeson CN, Cairo MS, Fenske TS, Freytes CO, Gale RP, Gibson J, Isola LM, Inwards DJ, Laport GG, Lazarus HM, Maziarz RT, Wiernik PH, Schouten HC, Slavin S, Smith SM, Vose JM, Waller EK, Hari PN; Lymphoma Working Committee of the CIBMTR. Bacher U, et al. Among authors: smith sm. Blood. 2012 Nov 15;120(20):4256-62. doi: 10.1182/blood-2012-06-436725. Epub 2012 Sep 24. Blood. 2012. PMID: 23007405 Free PMC article.
The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance).
Smith SM, Schöder H, Johnson JL, Jung SH, Bartlett NL, Cheson BD; Alliance for Clinical Trials in Oncology. Smith SM, et al. Leuk Lymphoma. 2013 Jul;54(7):1405-10. doi: 10.3109/10428194.2012.744453. Epub 2013 Jan 4. Leuk Lymphoma. 2013. PMID: 23194022 Free PMC article. Clinical Trial.
2,516 results